T. Izumi

发表

Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction

M. Uebayashi, N. Sakamoto, Y. Ono, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus‐infected patients with renal impairment

F. Sato, N. Sakamoto, M. Natsuizaka, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Hepatitis B: progress in understanding chronicity, the innate immune response, and cccDNA protection.

N. Sakamoto, K. Morikawa, T. Izumi, 2016, Annals of translational medicine.

The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease

T. Sugiyama, N. Sakamoto, S. Ohnishi, 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria

T. Miyagishima, N. Sakamoto, S. Ohnishi, 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis

H. Miyoshi, A. Nakamura, N. Sakamoto, 2018, PloS one.

L‐Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis

N. Sakamoto, S. Ohnishi, M. Natsuizaka, 2018, Hepatology communications.

Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150

T. Miyagishima, N. Sakamoto, S. Ohnishi, 2022, Cancers.

Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection

M. Kurosaki, N. Izumi, Hiroaki Haga, 2019, Journal of Gastroenterology.

Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients

M. Sugiyama, M. Mizokami, N. Sakamoto, 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C

F. Sato, N. Sakamoto, M. Natsuizaka, 2016, Journal of Gastroenterology.

Comparing the risk of hepatitis B virus reactivation between direct‐acting antiviral therapies and interferon‐based therapies for hepatitis C

N. Sakamoto, M. Natsuizaka, T. Sho, 2017, Journal of viral hepatitis.

Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter

N. Sakamoto, M. Natsuizaka, Masaru Baba, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy

A. Tsubota, Etsuko Iio, Yasuhito Tanaka, 2017, Journal of Gastroenterology.

Prevalence and characteristics of naturally occurring sofosbuvir resistance‐associated variants in patients with hepatitis C virus genotype 1b infection

T. Miyagishima, F. Sato, N. Sakamoto, 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1 b infection

T. Miyagishima, F. Sato, N. Sakamoto, 2016 .

Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation‐related hepatitis

N. Sakamoto, S. Ohnishi, M. Natsuizaka, 2023, Journal of medical virology.

Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases

N. Sakamoto, M. Natsuizaka, Masaru Baba, 2018, Internal medicine.

Add‐on effects of fluvastatin in simeprevir/pegylated‐interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study

N. Sakamoto, M. Natsuizaka, J. Yoshida, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Successful Treatment of Living Donor Liver Transplantation Patients with Recurrent Hepatitis C Virus by Interferon-Free Therapy with Direct-Acting Antivirals

K. Yamashita, R. Goto, M. Zaitsu, 2017 .

Hepatitis B virus X protein impairs α‐interferon signaling via up‐regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A

Yasuhito Tanaka, T. Wakita, K. Watashi, 2017, Journal of medical virology.

Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment

T. Miyagishima, N. Sakamoto, S. Ohnishi, 2022, Liver Cancer.

Increased serum C‐reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis

N. Sakamoto, T. Sho, K. Morikawa, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma

M. Nakanishi, N. Sakamoto, M. Chuma, 2017, Drugs in R&D.